Sharemaestro Newsreel

Analysts Have Been Trimming Their TELA Bio, Inc. (NASDAQ:TELA) Price Target After Its Latest Report

TELA Bio, Inc. missed its latest quarterly earnings expectations, reporting lower-than-anticipated revenues of US$19m and a larger loss per share of US$0.20. Following these results, analysts have reduced their 2026 revenue forecasts to US$82.4m and increased their loss per share estimates to US$0.77, leading …

Citigroup Adjusts Price Target on Stryker to $399 From $385, Maintains Buy Rating

Citigroup has increased its price target for Stryker (SYK) to $399 from $385, while reiterating a Buy rating on the stock. This adjustment reflects Citigroup's continued positive outlook on the medical equipment company. The article also lists other recent analyst adjustments and company news …

Citigroup Adjusts Price Target on DexCom to $105 From $88, Maintains Buy Rating

Citigroup has increased its price target for DexCom (DXCM) shares to $105 from $88, while reiterating a Buy rating on the stock. This adjustment reflects a more optimistic outlook from the firm regarding the medical equipment company. DexCom specializes in continuous glucose monitoring systems …

Haemonetics (HAE) Q1 2027 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8 a.m. ET CALL PARTICIPANTS Vice President, Investor Relations and Treasurer - Olga GuyetteChief Executive Officer - Christopher SimonChief Financial Officer - James D'Arecca TAKEAWAYS Net Revenue -- $339.4 million, representing 5.6% reported …

Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More

This article details Wall Street analyst upgrades, downgrades, and initiations for various companies on Thursday, August 13, 2026, following the release of inline CPI data. Key movements include Five Below being upgraded to Buy at Jefferies and StubHub being cut to Underperform at Bank …

LENSAR earnings beat by $0.31, revenue topped estimates

Earnings Update: Quanterix Corporation (NASDAQ:QTRX) Just Reported And Analysts Are Trimming Their Forecasts

Quanterix Corporation recently reported disappointing second-quarter results, with revenues falling 12% short of analyst estimates and statutory losses significantly exceeding expectations. Following this, analysts have made serious cuts to their revenue outlook for 2026, now expecting a 6.8% decline, and anticipate increased losses per …

CONMED (NYSE:CNMD) Upgraded to Hold at Zacks Research

Zacks Research has upgraded CONMED (NYSE:CNMD) from a "strong sell" to a "hold" rating, despite the broader analyst consensus remaining at "Reduce" with an average price target of $41.40. This upgrade follows CONMED's strong quarterly earnings report, where it exceeded EPS and revenue estimates, …

NeuroOne(R) Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%

NeuroOne Medical Technologies Corporation reported strong fiscal Q3 2026 financial results, with product revenue increasing 16% year-over-year to $2.0 million and gross margins expanding to 59.9%. The company also announced $2.7 million in new product orders, received ISO 13485 Certification for international expansion, and …

Integer Holdings (ITGR) Stock Looks Below Fair Value On Cash Flow But Above Fair Value On Earnings

GE HealthCare Technologies (NASDAQ:GEHC) Stock Rating Upgraded by Zacks Research

Zacks Research upgraded GE HealthCare Technologies (NASDAQ:GEHC) stock from "strong sell" to "hold." This upgrade aligns with a broader analyst consensus of "hold" and a target price of $77.73, following the company's strong quarterly earnings report where it surpassed EPS expectations and saw a …

LENSAR Q2 Revenue Rises 18% as Net Income Reaches $3.5 Million

LENSAR (LNSR) swings to Q2 2026 profit as revenue and ALLY usage climb

LENSAR, Inc. (LNSR) reported a significant swing to profit in Q2 2026, with net income of $3.5 million compared to a $1.8 million loss in the prior year, driven by an 18% increase in total revenue to $16.5 million. The company saw strong growth …

QRG Capital Management Inc. Buys 198,951 Shares of Boston Scientific Corporation $BSX

QRG Capital Management Inc. significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 121.5% in the second quarter, acquiring 198,951 additional shares and bringing its total holdings to 362,716 shares valued at $15.5 million. This comes amidst strong financial performance from Boston Scientific, …

Wasatch Advisors LP Buys 186,357 Shares of OrthoPediatrics Corp. $KIDS

Wasatch Advisors LP significantly increased its stake in OrthoPediatrics Corp. (NASDAQ:KIDS) by 56.6% in the second quarter, purchasing an additional 186,357 shares. This brings their total holdings to 515,677 shares, representing 2.01% of the company. OrthoPediatrics recently reported better-than-expected earnings, with a smaller loss …

Lumexa Imaging Holdings, Inc. Stock 12‑Month Price Target Cut to $16.43, Implies 40% Upside

The average 12-month price target for Lumexa Imaging Holdings, Inc. (LMRI) stock has been reduced by analysts from $17.29 to $16.43, despite still implying a 40% potential upside based on the latest closing price. Eight analysts maintain a "Buy" consensus rating for the company, …

Insulet Corporation (PODD) Stock forecasts

Argus has lowered its target price for Insulet Corporation (PODD) to $159.00 from its previous rating. Insulet, founded in 2000, aims to simplify continuous subcutaneous insulin infusion therapy for diabetes. The stock's current price is $144.68.

V. M. Manning & CO. Inc. Acquires New Position in Abbott Laboratories $ABT

V. M. Manning & CO. Inc. has acquired a new stake in Abbott Laboratories, purchasing 19,849 shares valued at approximately $1.8 million, making it their 11th largest holding. This move comes as Abbott Laboratories exceeded its quarterly earnings expectations and maintains a positive outlook …

Wasatch Advisors LP Has $20.49 Million Stock Position in TransMedics Group, Inc. $TMDX

Wasatch Advisors LP reduced its stake in TransMedics Group (NASDAQ:TMDX) by 10.9% in the second quarter but still holds 308,434 shares valued at $20.49 million. The company's recent earnings showed a revenue beat but an EPS miss, leading to mixed analyst ratings with an …

MaxCyte, Inc. $MXCT Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC significantly increased its stake in MaxCyte, Inc. (NASDAQ:MXCT) by 153.3% in the first quarter, acquiring an additional 1.206 million shares to own a total of 1.993 million shares, representing 1.86% of the company. Other institutional investors also built positions, with hedge …

Earnings call transcript: BrainsWay tops revenue forecasts in q2 2026

BrainsWay Ltd. reported strong second-quarter 2026 results, exceeding revenue forecasts with $17.1 million and matching adjusted EPS expectations at $0.07. The company raised its full-year 2026 revenue guidance to $68 million-$70 million, driven by strong demand for its Deep TMS systems and SWIFT accelerated …

Wasatch Advisors LP Sells 1,897,237 Shares of Cerus Corporation $CERS

Wasatch Advisors LP reduced its stake in Cerus Corporation by 35.9% in the second quarter, selling 1,897,237 shares but still retaining 3.38 million shares valued at approximately $9.9 million. Cerus reported quarterly revenue of $63.3 million and an adjusted loss of $0.01 per share, …

Western Wealth Management LLC Has $1.77 Million Stock Position in Medtronic PLC $MDT

Western Wealth Management LLC significantly increased its stake in Medtronic PLC by 271.2% in the first quarter, now holding 20,382 shares valued at $1.77 million. Medtronic maintains a "Moderate Buy" consensus among analysts with an average price target of $98.83, following solid Q1 earnings …

Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Consensus Rating of "Reduce" from Brokerages

5 Insightful Analyst Questions From Haemonetics’s Q2 Earnings Call

Boston Scientific Corporation $BSX Shares Purchased by Fisher Funds Management LTD

Fisher Funds Management LTD significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 17.1% in the second quarter, bringing its total holding to approximately $43 million. This comes as institutional investors collectively own 89.07% of BSX. Boston Scientific recently reported strong quarterly revenue …

Brookstone Capital Management Sells 233,448 Shares of Boston Scientific Corporation $BSX

Brookstone Capital Management significantly reduced its stake in Boston Scientific, selling 233,448 shares and retaining a smaller position. Despite this sale, institutional investors still hold a large percentage of the company, and analysts maintain a "Moderate Buy" rating. Boston Scientific recently surpassed quarterly earnings …

Outset Medical, Inc. (NASDAQ:OM) Given Average Recommendation of "Hold" by Analysts

Analysts have issued an average "Hold" recommendation for Outset Medical, Inc. (NASDAQ:OM), with a consensus 12-month price target of $10.00, significantly above its current trading price of $4.50. The company recently reported a quarterly loss of $0.80 per share, missing estimates, though revenue exceeded …

Renaissance Technologies LLC Trims Position in Delcath Systems, Inc. $DCTH

Renaissance Technologies LLC reduced its stake in Delcath Systems (NASDAQ:DCTH) by 57.1% in the first quarter, selling over 200,000 shares but still retaining a significant holding. Despite this, other institutional investors have increased their positions. The company reported strong Q1 revenue and earnings, surpassing …

Dimensional Fund Advisors LP Reduces Position in Inogen, Inc $INGN

Dimensional Fund Advisors LP significantly reduced its stake in Inogen, Inc. by 28.3% in the first quarter, selling over 200,000 shares but still retaining a substantial holding. Despite this reduction, other institutional investors have increased their positions, and Inogen's stock holds a "Moderate Buy" …

Price to sales forward of MaxCyte, Inc. – MUN:MYE0

This page from TradingView provides financial information for MaxCyte, Inc. (MUN:MYE0), specifically focusing on its forward price-to-sales ratio. The article indicates that market data is provided by ICE Data Services and reference data by FactSet, with SEC filings from Quartr.

TELA Bio, Inc. Revenue Breakdown – BOATS:TELA

TELA Bio, Inc. generated $80.28 million USD last year, with its OviTex segment being the top performer, contributing $51.22 million USD. The United States was the largest geographical contributor to the company's revenue, accounting for $68.17 million USD.

Haemonetics Corporation (NYSE:HAE) Receives Average Rating of "Moderate Buy" from Analysts

Haemonetics Corporation (NYSE:HAE) has received a consensus "Moderate Buy" rating from eleven research firms, with an average 12-month price target of $90.89. The company recently surpassed quarterly expectations, reporting $1.14 EPS and $339.38 million in revenue, leading several analysts to raise their price targets …

Lumexa outlines $235M-$241M 2026 adjusted EBITDA amid Hospital for Special Surgery joint venture expansion

Earnings Call Insights: Lumexa Imaging Holdings, Inc. (LMRI) Q2 2026 MANAGEMENT VIEW * CEO Caitlin Zulla said, "Q2 was a quarter of substantial progress as we continue to execute against the strategic priorities," and highlighted "driving strong same-center growth with an expanding mix of …

Boston Scientific Corp (BSX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Boston Scientific Corp (BSX), detailing its current price momentum score, support and resistance levels, and various technical indicator readings. It also includes an analysis of moving averages and addresses frequently asked questions regarding technical ratings and moving …

Rep. Mike Kelly Unloads Abbott Laboratories (NYSE:ABT) Shares

Representative Mike Kelly sold shares of Abbott Laboratories (NYSE:ABT) valued between $1,001 and $15,000 on July 17th, as well as shares of PepsiCo and Walt Disney on the same day. This sale occurred despite Abbott Laboratories reporting a quarterly earnings beat and reaffirming its …